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Diabetes is the fourth major cause of death in Taiwan. High blood glucose can lead to mac-
rovascular diseases, small vessel diseases (retinopathy, kidneydisease), andneuropathy. This
study aimed to investigate whether Monascus-fermented products (ANKASCIN 568 plus) can
regulate blood glucose and blood lipids. This study enrolled 39 patients with a fasting blood
glucose level between 100 mg/dL and 180 mg/dL, and a glycated hemoglobin (HbA1c) level of
<9%. All patients were randomly divided into placebo (n¼ 20) and experimental (n¼ 19)
groups. Each patient received two placebo capsules (maltodextrin) or ANKASCIN 568 plus
capsules daily for 12 weeks. The patients were screened during follow-up 4 weeks after the
administration of sample or placebo had been discontinued. Blood and urine samples were
collected at the initial, 6th week, 12th week, and 16th week. The anthropometric indicators of
blood pressure, fasting plasma glucose level, postprandial plasma glucose level, insulin level,
insulin resistance, blood lipid changes, and liver, kidney, and thyroid function indices were
measured.After 6weeks, changes in fastingbloodglucose, low-density lipoprotein cholesterol
(LDL-C), and total cholesterol (TC) levels showed thatANKASCIN568plushadamore favorable
effect than the placebo. Compared to baseline, a statistically significant decrease of 8.5%,
10.3%, and 7.5% was observed in fasting blood glucose, LDL-C and, TC levels, respectively
(p< 0.05 for all pairs). Therefore, ANKASCIN 568 plus produced byMonascus purpureusNTU 568
fermentation may be a potentially useful agent for the regulation of blood glucose and blood
lipids and for treatment of coronary artery diseases.
Copyright © 2016, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).chemical Science and T
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Diabetes mellitus (DM) is a common chronic disease and is
associated with a high risk of major complications such as
blindness, renal disease, foot ulcers, and cardiovascular dis-
ease, which account for 50% of all diabetes-related fatalities
and lead to considerable disability [1]. The major site of
impaired insulin-stimulated glucose utilization is the skeletal
muscle; Type 2 DM (DM2) patients show reduced glucose up-
take, glycogenesis, and glucose oxidation in the skeletal
muscle [2,3].
Insulin-stimulated glucose uptake is impaired and sup-
pression of lipolysis is decreased in the adipocytes of DM2
patients [4,5], although responsiveness to insulin might vary
considerably between different adipose depots. The resulting
elevated circulating free fatty acid levels disrupt the gluco-
seefatty acid (Randle) cycle, thereby aggravating insulin
resistance (IR) in the muscle and liver cells and resulting in
insulin-induced suppression of hepatic glycogenolysis. IR is a
pathogenic condition that plays a key role in the development
of metabolic and hemodynamic alterations and is thus
responsible for the onset of the so-called cardiometabolic
syndrome [6]. Given the differences among tissueswith regard
to insulin dependence and sensitivity, manifestations of IR
syndrome are likely to reflect the composite effects of excess
insulin and variable resistance to its actions [7,8]. Chronic
physical conditions have been associated with an increased
risk of depression in a range of cultural settings [9e12], and
the risk has been shown to increase with the number of
conditions [13].
At present, DM2 is often treated with pioglitazone. Ac-
cording to the Naranjo probability scale, pioglitazone might
induce rhabdomyolysis, i.e., rapid breakdown of muscle cells
leading to the release of intracellular contents into the circu-
lation [14]. This conclusion was based on the exclusion of
potential medical causes, such as hypothyroidism, infection,
muscle trauma, alcoholism, patient drug exposure, and the
observed resolution of signs and symptoms when pioglita-
zone was withdrawn [15]. Similarly, statins, which are the
most widely prescribed class of cholesterol-lowering drugs
[16], might induce rhabdomyolysis via various mechanisms
[17].
Monascus fungal species have been used in preparing
traditional foods in Eastern Asia for several centuries. In our
previous studies, we showed that Monascus-fermented rice,
known as red mold rice (RMR), has antioxidative effects [18]
and is useful for the treatment of Alzheimer's disease [19]. In
our previous study, we investigated the effects of a combi-
nation of Monascus-fermented products and lovastatin on
rhabdomyolysis in hyperlipidemic hamsters [20]. In addition,
we also investigated Monascus-fermented products, a poten-
tially functional food, with pioglitazone in the treatment of
streptozotocin-induced diabetes rats [21]. Monascus species
produce several kinds of pigments, which are functional sec-
ondary metabolites. These include the yellow pigments
ankaflavin and monascin, the orange pigments monascoru-
brin and rubropunctanin, and the red pigments monascor-
ubramine and rubropuctamine [22]. Monascin and ankaflavin
have numerous biological effects such as inhibition ofPlease cite this article in press as: Wang Y-R, et al., A randomized, dou
plus on blood glucose regulation, Journal of Food and Drug Analysisnonalcoholic fatty liver, amelioration of pancreatic damage
and hyperglycemia in patients with diabetes, and antioxidant
and antiinflammatory activities [23e25]. These compounds
are peroxisome proliferator-activated receptor (PPAR)-g ago-
nists that subsequently initiate the transcription of down-
stream genes. Considering the reported health benefits of
monascin and ankaflavin, which are themajor constituents of
Monascus purpureus NTU 568 fermented products, this clinical
trial was conducted on the recommendation of the Food and
Drug Administration, Taiwan, to evaluate the effects of oral
administration of two capsules of ANKASCIN 568 plus (M.
purpureus NTU 568 fermented product) daily on blood glucose
and blood lipid regulation by evaluating the liver somatic
index, kidney index, and muscle index.2. Materials and methods
2.1. Materials
The study material consisted of ANKASCIN 568 plus product
fermented byM. purpureusNTU 568, which was obtained from
SunWay Biotech., Co., Ltd. (Taipei, Taiwan, R.O.C.). Two cap-
sules (500 mg/capsule) of ANKASCIN 568 plus powder con-
tained 6 mg of monascin and 3 mg ankaflavin. The same
capsules containing maltodextrin were used as a placebo.
2.2. Patients
The study was conducted between September 2012 and
November 2014 at Chung Shan Medical University, Taichung,
Taiwan, after approval was received from the Institutional
Review Board of the Taichung Chung Shan Medical University
Hospital (Institutional Review Board proof document CHMUH
No: CS12120). In total, 377 patients with diabetes in a series of
stages were screened. In the first stage, 67 ‘subhealthy’ pa-
tients with fasting glucose levels in the range of 100e125 mg/
dL and glycated hemoglobin (HbA1c) 5.7e6.4% were included.
Of these, 28 patients withdrew from the trial because of the
development of some disease; thus, 39 patients completed
this study. Written informed consent was obtained from all
enrolled patients. The treatment and placebo groups included
19 patients and 20 patients, respectively.
During the trial, patients with hypertension were not
allowed to use depressor drugs unless their blood pressure
elevated suddenly. Patients with coronary heart disease were
also not allowed to use analgesics unless they experienced
symptoms of angina pectoris. All patients were on a low-
cholesterol diet throughout the treatment period. Carotid ul-
trasound examinations and plasma biochemical assays were
performed at the end of the treatment.
2.2.1. Inclusion and exclusion criteria
Inclusion criteria included the following: (A) age: 18e65 years;
(B) fasting glucose range: 100e125mg/dL; (C) HbA1C: 5.7e6.4%;
(D) body mass index: 23e30 kg/m2; and (E) administration of
hypolipidemic, antihypertensive, or diabetes drugs stabilized
for at least 3 months (if used). Exclusion criteria were as fol-
lows: (A) administration of antidiabetic drugs; (B) inconsistent
or unstable administration of drugs that might interfere withble-blind clinical study to determine the effect of ANKASCIN 568
(2016), http://dx.doi.org/10.1016/j.jfda.2016.06.011
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eases and administration of drugs for treatment of these
diseases; (D) confirmation of thyroid, liver, renal, or muscular
diseases; (E) known allergy or intolerance to a component of
the test product; and (F) anymedical or surgical condition that
could lead to an inconsistent adherence to the study protocol.
2.3. Methods
2.3.1. Randomization, treatment, and follow-up
The patients were visited by investigators and informed about
the rationale and main aims of the study. A written informed
consent was obtained from the patients. Block randomization
was used for treatment allocation. The patients were
randomly assigned to groups. One group received ANKASCIN
568 plus standard (treatment group) and the other group
received placebo (control group). The study was double-blind.
The patients were also advised not to use antidiabetic drug
regimen during the study.
2.3.2. Endpoints
The designated study endpoint of both trials was the inci-
dence of adverse events. Additional safety endpoints included
serious adverse events, adverse events leading to the discon-
tinuation of the study health food (for patients in the
ANKASCIN 568 plus group), and abnormalities in creatine ki-
nase levels, liver and kidney function, and electrolyte balance.
A prespecified exploratory outcome was defined as the inci-
dence of confirmed cardiovascular events, which was ascer-
tained over the course of the study.
2.4. Statistical analysis
Data are expressed as the mean± standard deviation. The
statistical significance of differences in the biochemical ana-
lyses was determined using one-way analysis of variance
(ANOVA) by using the general linear model procedure of the
Statistical Package for the Social Sciences (SPSS 16.0) software
(SPSS Institute, Inc., Chicago, IL, USA). This was followed by an
ANOVA with a paired t-test to evaluate the differences beforeTable 1 e Effect of chronic administration of ANKASCIN 568 plu
Treatment
0 6 12 16
(Initial) (Follow-
Week
Age (y) 60.9 ± 15.1
Weight (kg) 68.2 ± 9.0 68.8± 9.3 68.9± 9.7 69.4± 9.
Body fat (%) 30.6 ± 6.8 30.7± 6.9 30.9± 7.4 31.3± 6.
BMI 25.2 ± 2.1 25.4± 2.0 25.5± 2.1 25.4± 2.
Waist (cm) 86.2 ± 7.3 86.8± 7.5 86.2± 8.2 85.5± 8.
Blood pressure
SBP (mmHg) 137.5 ± 17.2 138.5± 15.7 142.0± 18.1 142.2± 1
DBP (mmHg) 79.3 ± 15.0 80.8± 12.5 79.6± 13.2 82.2± 12
Data are expressed as the mean± standard deviation.
Student t-test showed no significant difference between placebo and trea
* p < 0.05 versus Week 0 for each group.
BMI¼ body mass index; DBP¼ diastolic blood pressure; SBP¼ systolic blo
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Student t test was used to compare the differences between
test and placebo groups (p< 0.05).3. Results
3.1. Anthropometric measurements
The body weight, body mass index, waistline, and blood
pressure of the participants in this trial are shown in Table 1.
There were no differences in these values among the groups
during the course of the experiment. Therefore, we can
conclude that the appearance and health condition of partic-
ipants were maintained during the trial.
3.2. Effect of ANKASCIN 568 plus on glycemic index
In this trial, the first aim was to determine the effect of
ANKASCIN 568 plus capsules on hyperglycemic patients. In
our previous study, fermented products of M. purpureus NTU
568 were found to improve glucose metabolic syndrome-
related indicators, including effective improvement of blood
insulin levels, reduction of fasting blood glucose levels, and
amelioration of IR and other effects. Animal test results sug-
gested that streptozotocin-induced diabetic rats provided
with RMR at 200 mg/kg daily for up to 8 weeks presented a
significantly lower fasting blood glucose level than diabetic
rats fed a normal diet [26].
After 6 weeks of administration of ANKASCIN 568 plus,
fasting glucose levels were significantly reduced (8.5%, Table 2).
Even 4 weeks after the test sample was discontinued, fasting
glucose levels were lower than the initial level. No difference in
the fasting glucose level was found in the placebo group. For
glucose tolerance, postprandial blood glucose (post cibum)
values remained unchanged. HbA1c is a reliable estimate of the
mean plasma glucose levels over the previous 3e4 months for
most individuals with diabetes, and as the basis for treatment
adjustment. Higher blood glucose correlates to higher HbA1c;
furthermore, since red blood cells have a lifespan of 120 days,s or placebo on anthropometric measurements of patients.
Placebo
0 6 12 16
up) (Initial) (Follow-up)
Week
59.1± 14.5
6* 70.5± 13.3 70.2± 12.9 70.2± 13.4 69.9± 12.8
3 32.2± 6.9 33.0± 6.5 31.4± 6.9 31.7± 6.9
5 25.2± 2.1 26.1± 4.3 26.2± 4.3 25.6± 3.8
3 90.9± 11.8 90.0± 11.7 90.1± 11.6 90.1± 11.6
8.4 132.5± 16.6 133.1± 16.3 137.5± 18.0 133.3± 14.7
.1 84.4± 18.8 85.3± 16.7 87.4± 13.9 87.0± 18.1
tment group at Week 0.
od pressure.
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Table 2 e Effect of chronic administration of ANKASCIN 568 plus or placebo on glycemic index of patients.
Treatment Placebo
0 6 12 16 0 6 12 16
(Initial) (Follow-up) (Initial) (Follow-up)
Week Week
FBG (mg/dL) 115.3± 12.0 105.5± 15.7* 104.6 ± 12.1* 110.2 ± 7.2* 118.8± 16.3 117.4± 22.1 114.6± 28.3 118.6± 22.1
PC (mg/dL) 143.5± 22.5 110.7± 31.7 165.3 ± 68.8 133.0 ± 16.0 138.4± 52.9 131.2± 45.9 128.8± 52.0 126.1± 47.6
HbA1c (%) 5.9± 0.7 5.9± 0.7 6.0 ± 0.7 6.0 ± 0.6 6.1± 0.7 6.1± 0.9 6.1± 1.1 6.2± 1.0
Insulin (mg/dL) 10.8± 5.4 11.9± 6.1 11.1 ± 4.9 11.6 ± 1.4 12.2± 7.5 12.3± 7.5 13.1± 10.0 12.6± 7.2
HOMA-IR 1.4± 0.7 1.6± 0.8 1.5 ± 0.6 1.5 ± 0.8 1.6± 1.0 1.7± 1.0 1.8± 1.3 1.9± 0.9
Data are expressed as the mean ± standard deviation.
Student t-test showed no significant difference between placebo and treatment group at Week 0.
* p< 0.05 versus Week 0 for each group.
FBG¼ fasting blood glucose; HbA1c¼ glycated hemoglobin; HOMA-IR¼homeostasis model assessment of insulin resistance; PC¼ post cibum.
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months. A normal HbA1c value is about 5%, based on clinical
findings. For adequate control of diabetes, HbA1c value should
remain below 7% to reduce the risk of complications including
cerebrovascular disease, cardiovascular disease, retinopathy,
peripheral neuropathy, and renal dysfunction. The HbA1c
values of the test group were lower than those of the placebo
group were, although not statistically significant (Table 2).
However, the data can be considered to exemplify a single case
of downward trending HbA1c, and can be attributed to the fact
that patients needed to adjust to the consumption of the RMR
product to maintain blood glucose. Homeostasis model
assessment of IR (HOMA-IR) studies have indicated that a level
of 1.95 can be considered as IR [27]; however, in the present
study, HOMA-IR values were not different between the two
groups (Table 2). This could be becauseall patientshadanormal
status, with weak blood glucose control. Taken together, these
results indicate that the administration of ANKASCIN 568 plus
could effectively improve blood glucose regulation.
3.3. Hypolipidemic effect of ANKASCIN 568 plus
We used capsules containing ANKASCIN 568 plus fermented
by M. purpureus NTU 568 as the study material. The total
cholesterol (TC) levels at Week 0 were not significantlyTable 3 e Effect of chronic administration of ANKASCIN 568 pl
Treatment
0 6 12 16
(Initial) (Follow
Week
TG (mg/dL) 141.5 ± 84.0 133.3± 47.7 117.0± 55.5 130.3±
TC (mg/dL) 198.5 ± 38.7 183.6± 41.2* 194.5± 36.0 191.6±
HDL-C (mg/dL) 49.0 ± 6.9 46.1± 8.1 48.7± 6.7 46.6± 9
LDL-C (mg/dL) 125.9 ± 34.6 112.9± 38.5* 120.9± 32.7* 123.6±
LDL-C/HDL-C 2.6 ± 0.4 2.4± 0.3* 2.5± 0.5* 2.7± 0.
TC/HDL-C 4.1 ± 0.3 4.0± 0.5 4.0± 0.4 4.1± 0.
Data are expressed as the mean ± standard deviation.
Student t-test showed no significant difference between placebo and trea
* p< 0.05 versus Week 0 for each group.
HDL-C¼ high-density lipoprotein cholesterol; LDL-C¼ low-density lipopr
Please cite this article in press as: Wang Y-R, et al., A randomized, dou
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The TC levels for the treatment groups after 6 weeks of
treatment with ANKASCIN 568 plus decreased significantly by
7.5% compared to that at Week 0 (p< 0.05). Serum triglyceride
(TG) levels in the treatment and placebo groups were
compared at Weeks 0, 6, 12, and 16 (Table 3). The results
revealed that there were no differences between the treat-
ment and placebo groups. However, the TG values did show
considerable differences among patients in each group. This
intragroup variability might have resulted in the lack of sta-
tistically significant differences between the treatment and
placebo groups. However, the test substance-treated group
showed a difference between the values obtained before
(Week 0) and after 6 weeks of treatment. TG levels showed a
downward trend, indicating that ANKASCIN 568 plus capsules
effectively reduced the TG levels.
3.4. Effect of ANKASCIN 568 plus on serum lipid profile
Low-density lipoprotein cholesterol (LDL-C) and high-density
lipoprotein cholesterol (HDL-C) levels can be used to deter-
mine the lipid metabolic status; in humans, the standards are
<130 mg/dL and > 40 mg/dL, respectively. Extremely low HDL-
C or high LDL-C levels are thought to have a considerable
impact on cardiovascular health. In this study, the LDL-C levelus or placebo on blood lipid profiles of patients.
Placebo
0 6 12 16
-up) (Initial) (Follow-up)
Week
59.9 160.8± 92.4 168.4± 103.7 158.4 ± 85.7 165.0± 94.5
33.0 199.6± 44.7 199.5± 46.5 202.6 ± 46.6 197.7± 23.0
.8 45.8± 8.7 44.1± 10.1 46.3 ± 10.1 41.5± 7.5
37.8 122.9± 40.4 124.1± 42.2 123.6 ± 41.1 122.4± 40.3
3 2.7± 0.6 2.8± 0.6 2.7 ± 0.5 2.9± 0.5
5 4.4± 0.3 4.5± 0.5 4.4 ± 0.3 4.8± 0.4
tment group at Week 0.
otein cholesterol; TC¼ total cholesterol; TG ¼ triglyceride.
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of the treatment group at Week 0.
The LDL-C levels of the ANKASCIN 568 plus-treated and
placebo groups were compared at Weeks 0, 6, and 12 (Table 3);
the LDL-C level decreased by 10.3% and 4.0% (p< 0.05 for all
pairs) at 6 weeks and 12 weeks, respectively. The HDL-C levels
were not different between the ANKASCIN 568 plus-treated
and placebo groups (Table 3; p> 0.05). These results indi-
cated that the treatment group showed significant improve-
ment in LDL-C but not HDL-C levels over time.
Ratios of LDL-C/HDL-C and TC/HDL-C that are >3.5 and
>5.0, respectively, are considered risk factors for cardiovas-
cular disease (including heart disease and stroke) and
atherosclerosis. Therefore, the changes in LDL-C/HDL-C and
TC/HDL-C ratios were determined in this study. The results
showed that the LDL-C/HDL-C ratios decreased by 7.8% and
3.8% at 6 weeks and 12 weeks, respectively (Table 3; p< 0.05).
In addition, the TC/HDL-C ratios for the treatment and pla-
cebo groups were not significantly different when comparing
Weeks 0, 6, 12, and 16 (Table 3). This finding was contradic-
tory to that for the TG outcome, which showed a lack of
significant difference; this could be because the ratios are
easily affected by various factors, including the patient’s
blood parameters and the diet consumed the day before
testing. Control of these factors is typically more difficult in
humans than in animals. Furthermore, the results suggest
that ANKASCIN 568 plus capsules could effectively improve
lipid metabolism and reduce the risk of hardening of the
arteries and the probability of developing coronary athero-
sclerosis and heart disease. Increased LDL-C levels have been
associated with atherosclerosis and other cardiovascular
diseases. These results suggest that the functional compo-
nents of ANKASCIN 568 plus can effectively reduce blood
LDL-C levels and thus possibly reduce the incidence of car-
diovascular diseases.Table 4 e Effect of chronic administration of ANKASCIN 568 pl
Treatment
0 6 12 1
(Initial) (Follo
Week
Liver function
AST (IU/L) 22.4± 6.1 24.2± 6.5 19.9± 4.1* 20.1
ALT (IU/L) 23.8± 10.7 24.1± 9.7 19.9± 6.0* 20.8
g-GT (IU/L) 23.5± 17.7 26.3± 27.4 20.6± 15.6 21.4
Albumin (g/dL) 4.2± 0.3 4.1± 0.3 4.1± 0.3 4.2±
Kidney function
Creatinine (mg/dL) 0.9± 0.3 0.9± 0.3 0.9± 0.3 0.8±
BUN (mg/dL) 14.5± 6.1 13.8± 4.6 14.7± 5.0 14.4
Electrolyte balance
Ca (mg/dL) 9.4± 0.3 9.3± 0.3 9.1± 0.2 9.0±
Na (mmol/L) 139.0± 2.8 138.9± 2.3 138.2± 2.0 137.
K (mmol/L) 4.5± 0.7 4.6± 0.7 5.1± 1.2 4.2±
Cl (mmol/L) 104.6± 3.2 104.7± 2.1 104.8± 2.7 105.
Data are expressed as the mean± standard deviation.
Student t-test showed no significant difference between placebo and trea
* p < 0.05 versus Week 0 for each group,
ALT¼ alanine aminotransferase; AST¼ aspartate aminotransferase; g-GT
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Most commercial red mold fermented products contain
citrinin, which is toxic to the liver and kidney. Therefore, the
food safety risks associatedwith redmold fermented products
should be evaluated. The safety of the products was evaluated
by assaying the liver levels of aspartate aminotransferase
(AST) and alanine aminotransferase (ALT).
Different treatment weeks within the same group were
compared, showing that there was no significant difference in
the AST and ALT levels between the placebo and ANKASCIN
568 plus groups (Table 4). Gamma-glutamyltransferase (g-GT),
a membrane-bound heterodimeric glycoprotein, is abundant
in many tissues, including the kidney, intestine, and liver.
Under pathological conditions, when liver cells are damaged,
g-GT is released into the serum. The g-GT levels between the
treatment and placebo groups were not significantly different
over the course of the experiment (p> 0.05, Table 4). Blood
urea nitrogen (BUN) is a type of protein metabolite, and a high
concentration is indicative of weak renal excretion. BUN and
creatinine levels (Table 4) were not significantly different be-
tween the treatment and placebo groups (p> 0.05). Further-
more, there were no significant differences in the serum
calcium, sodium, potassium, and chloride concentrations
between the treatment and placebo groups (p> 0.05, Table 4).
These results indicate that administration of the test sub-
stance had no significant effect on renal metabolism and
physiological function.3.6. Effect of ANKASCIN 568 plus on serum thyroid
function and creatine phosphokinase levels
Thyroid-stimulating hormone (also known as thyrotropin,
TSH, or human TSH) is a pituitary hormone that stimulates
the thyroid gland to produce thyroxine (T4) and thenus or placebo on the liver and kidney functions of patients.
Placebo
6 0 6 12 16
w-up) (Initial) (Follow-up)
Week
± 3.6 33.7± 18.7 30.5± 18.3 30.2 ± 15.1 27.2± 11.5*
± 6.3 37.4± 29.2 33.2± 25.2 31.8 ± 19.8 29.9± 15.0
± 18.5 43.8± 33.0 39.4± 32.9 40.8 ± 37.7 37.7± 34.6
0.3 4.2± 0.3 4.1± 0.3 4.1 ± 0.3 4.1± 0.4
0.2 1.0± 0.3 0.9± 0.3 0.9 ± 0.2 1.2± 0.4
± 4.2 16.3± 6.9 15.0± 6.0 15.8 ± 6.3 16.1± 5.9
0.2 9.1± 0.6 9.3± 0.5 9.2 ± 0.5 8.9± 0.6
2± 2.9 139.1± 2.0 139.3± 2.2 137.5 ± 2.0 136.9± 2.9
0.5 4.6± 1.1 4.4± 0.8 4.3 ± 0.8 4.3± 0.9
7± 1.7 104.7± 2.8 105.2± 2.3 104.5 ± 2.5 104.1± 3.6
tment group at Week 0.
P¼ g-glutamyl transpeptidase.
ble-blind clinical study to determine the effect of ANKASCIN 568
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Table 5 e Effect of chronic administration of ANKASCIN 568 plus or placebo on the thyroid function and creatine
phosphokinase level of patients.
Treatment Placebo
0 6 12 16 0 6 12 16
(Initial) (Follow-up) (Initial) (Follow-up)
Week Week
Free T4 (ng/dL) 0.9± 0.1 0.9± 0.1 0.9± 0.2 0.9 ± 0.1 1.0 ± 0.2 0.9± 0.2 1.0 ± 0.2 1.1± 0.3
TSH (mIU/mL) 2.1± 1.1 2.4± 1.4 2.5± 1.6 2.3 ± 1.1 2.0 ± 1.5 2.0± 1.1 3.0 ± 5.3 2.1± 1.3
CPK (IU/L) 99.0± 41.9 120.6± 59.5 92.2± 39.0 99.3 ± 43.6 104.7 ± 52.9 98.2± 70.3 95.4 ± 36.0 94.5± 36.0
Data are expressed as the mean ± standard deviation.
Student t-test showed no significant difference between placebo and treatment group at Week 0.
* p< 0.05 versus Week 0 for each group.
CPK¼ creatine phosphokinase; TSH¼ thyroid stimulating hormone.
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every body tissue. TSH is a glycoprotein hormone synthesized
and secreted by thyrotrope cells in the anterior pituitary
gland, which regulates the endocrine function of the thyroid.
The serum TSH level is often interpreted in conjunction with
free T4. TSH levels decrease and increase in hyperthyroidism
and hypothyroidism, respectively, and high levels of free TSH
(free T4) are indicative of hyperthyroidism and low organic
energy. In this study, no significant differences in free T4 and
TSH levels were found between the groups, with values
remaining in the normal range, indicating that administration
of ANKASCIN 568 plus did not affect thyroid function (Table 5).
During rhabdomyolysis, damaged muscle cells release crea-
tine phosphokinase (CPK), which is often used in the diagnosis
and monitoring of clinical myocardial infarction and muscle
diseases. As shown in Table 5, the CPK of the treatment group
at Week 0 andWeek 6 was not statistically different, owing to
large differences in standard deviation. Administration of
ANKASCIN 568 plus did not increase the CPK levels of the
treated patients (Table 5). Lipid peroxidation and oxidative
modification of LDL have been implicated as causal factors in
the pathogenesis of atherosclerosis. Therefore, prevention of
LDL oxidation by antioxidants might be an effective strategy
for inhibiting disease progression. Furthermore, oxygen-
derived radicals impair endothelial function and have been
implicated as mediators of this process.4. Discussion
RMR has been used as a dietary supplement in East Asia for
several centuries, especially in China and Japan. Our previous
study showed that Monascus fermentation using a dioscorea
substrate resulted in higher levels of monascin, ankaflavin,
and g-aminobutyric acid [28]. Monascus-fermented products
can be used as food-based adjuvants for diabetic patients to
ameliorate IR and/or impaired glucose metabolism [29]. This
study showed that Monascus-fermented products of ANKAS-
CIN 568 plus significantly decreased blood glucose levels at
Week 6 and Week 12, and after discontinuation of the treat-
ment (Table 2), providing direct evidence for the anti-
hyperglycemic effects of ANKASCIN 568 plus. Additionally,
the treated group showed changes in TC and LDL-C levels, as
well as LDL-C/HDL-C ratios (Table 3) and a significantPlease cite this article in press as: Wang Y-R, et al., A randomized, dou
plus on blood glucose regulation, Journal of Food and Drug Analysishyperglycemic effect. Furthermore, the LDL-C/HDL-C ratios
were significantly lower in the ANKASCIN 568 plus-treated
group than in the placebo group. LDL-C is a key indicator for
assessing coronary heart disease and is an important human
lipoprotein cholesterol that can be transported to body cells
for use. However, high blood levels of LDL-C result in its
accumulation in vessel walls, leading to atherosclerosis,
which blocks blood vessels. Therefore, high LDL-C is consid-
ered a risk factor for vascular obstruction. In contrast, HDL-C
is an important component for the in vivo prevention of arte-
riosclerosis. Low levels of HDL-C are an important predictor of
coronary atherosclerosis and coronary heart disease. High TG
level is the main cause of low HDL-C. Therefore, the positive
effects of ANKASCIN 568 plus on HDL-C suggest potential
benefits for coronary heart disease.
The levels of both AST and ALT, which are enzymes found
in liver cells, increase in response to inflammation and dam-
age to liver cells. However, destruction and injury to red blood
cells, heart, muscle, and other types of cells cause an increase
in AST but not ALT levels. Thus, ALT levels are more accurate
indicators of liver disease. Although changes in serum protein
composition in response to different diseases vary, an exces-
sively low total serum protein level generally indicates the
presence of chronic disease or liver damage. Because most
commercially available red mold products contain citrinin, a
hepatotoxin and nephrotoxin, we assessed the safety of our
products by measuring the levels of AST and ALT in the liver.
The AST, ALT, and g-GTP levels in our clinical trial were not
significantly different from those of the control (Table 4).
Potassium and calcium are themost important electrolytes
in the human body [30,31]. The serum glucose concentration
and total carbon dioxide content correlate significantly with
the serum potassium concentration, and the most common
cause of hyperkalemia (potassium overload) is kidney disease
[32]. Previously, no consistent or marked decrease in the
concentration of sodium and chloride was reported in rats
with diabetes insipidus, but a typical increase in potassium
levels was noted [33]. BUN is a type of protein metabolite, and
a high concentration of BUN indicatesweak renal excretion. In
the present study, the minor changes in this marker (Table 4)
suggested a lack of ANKASCIN 568 plus-induced toxic effects
on the liver and renal function as well as electrolyte balance,
also rhabdomyolysis was not induced following 12 weeks of
treatment. Deterioration of renal function leads to an increaseble-blind clinical study to determine the effect of ANKASCIN 568
(2016), http://dx.doi.org/10.1016/j.jfda.2016.06.011
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tion is an important indicator of kidney function. Further-
more, creatinine levels are also an important indicator of
renal function, and increased creatinine levels are indicative
of abnormalities. The in vivo extracellular cation sodium plays
an important role in maintaining osmotic pressure by regu-
lating the body fluid balance, whereas potassium prevents
muscle contraction and nerve conduction. The kidneys
excrete excess potassium in the plasma. Administration of
ANKASCIN 568 plus resulted in no significant effect on the
metabolic or physiological functions of the kidneys.
In addition, the anthropometric measurements were not
different after 12 weeks of intervention in the test and placebo
groups. Similar results were obtained with regard to blood
pressure (Tables 1 and 5). This result clearly indicates that the
risk of cardiovascular diseases could be greatly reduced by the
administration of ANKASCIN 568 plus. In this study, no effect
was observed on liver and kidney function (Table 4).5. Conclusion
This study suggests that patients who were administered two
capsules (500 mg/capsule) of ANKASCIN 568 plus daily for
more than 6 weeks exhibited a significant reduction in serum
blood glucose, TC, and LDL-C levels. The blood glucose was
well regulated in the treated patients. Therefore, ANKASCIN
568 plus produced by M. purpureus NTU 568 fermentation
might be a potentially useful agent for regulation of blood
glucose and blood lipids and treatment of DM2 and coronary
artery diseases.Conflicts of interest
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